Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis.
暂无分享,去创建一个
J. Bergerat | A. Bohbot | P. Dufour | A. Faradji | H. Frost | M. Wiesel | J. Siffert | M. Eber | M. Schmitt-Goguel | C. Lallot
[1] J. Murray,et al. Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. , 1990, Journal of biological response modifiers.
[2] T. Ulich,et al. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. , 1989, Blood.
[3] L. Aarden,et al. Interleukin 6 is involved in interleukin 1‐induced activities , 1988, European journal of immunology.
[4] H. Stevenson,et al. The treatment of cancer with activated cytotoxic leukocyte subsets. , 1988, Artificial organs.
[5] P. Poindron,et al. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture. , 1988, Anticancer research.
[6] P. Lansdorp,et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[7] Sugarbaker Ph,et al. Ex vivo activated monocytes and adoptive immunotherapy trials in colon cancer patients. , 1986 .
[8] I. Fidler,et al. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. , 1985, Cancer research.
[9] S. Sone,et al. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. , 1984, Journal of immunology.
[10] H. Stevenson. Isolation of human mononuclear leukocyte subsets by countercurrent centrifugal elutriation. , 1984, Methods in enzymology.
[11] J. Vilček,et al. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. , 1983, Journal of immunology.
[12] I. Fidler,et al. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. , 1983, Cancer research.
[13] A. Mantovani,et al. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: Augmentation by interferon, lymphokines and endotoxin , 1981, International journal of cancer.
[14] L. Zwelling,et al. DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPY , 1980, The Lancet.
[15] A. Mantovani,et al. Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors. , 1980, Journal of the National Cancer Institute.
[16] B. Gormus,et al. Human monocyte-induced tumor cell cytotoxicity. , 1978, Blood.
[17] I. Fidler. Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. , 1974, Cancer research.